Although currently small and narrowly focussed on a few disease areas and countries, the Biosimilars landscape is set to expand as patents expire on leading biologics, US legislation comes into effect, vision for pharma emerging markets and payers push for their wider adoption to manage burgeoning costs. The signs are visible, but questions remain. How […]